A cure for lung cancer?

Written by: Dr Neal Navani
Published: | Updated: 29/04/2020
Edited by: Bronwen Griffiths

Dr Neal Navani is one of the UK's leading respiratory medicine specialists who has a clear view on the importance of lung cancer screening as a means of preventing and lowering the rates of lung cancer mortality. 

How common is lung cancer in the UK?

Unfortunately, lung cancer remains the largest cause of cancer death in the UK. There are over 40,000 cases diagnosed each year and more than 30,000 people in the UK die of lung cancer each year. It has recently overtaken breast cancer as the most common cause of cancer death in women. It remains an enormous public health problem in the UK and worldwide and deserves urgent attention.

How important is lung cancer screening?

Lung cancer screening has been shown to save lives. In a trial in the USA published in 2011, lung cancer screening demonstrated a 20% reduction in mortality from lung cancer and over a 6-7% reduction in overall mortality in the general population. In other words, lung cancer screening with low-dose chemotherapy treatment has been proven to save lives. It has now been implemented as a major screening program in the USA, but pending further information, it has yet to be implemented in the UK.

How can lung cancer screening help in the treatment and prevention of lung cancer?

One of the major causes of poor survival for patients with lung cancer is late detection. This means that the majority of patients who present with lung cancer have advanced disease and therefore cannot be cured. Lung cancer screening offers a major opportunity to detect these patients’ lung cancer at an earlier stage where a cure is possible. Currently, approximately 18% of lung cancer patients in the UK can be cured by surgery, however, the implementation of a lung cancer screening program could potentially increase this figure up to 60%.

How can I ask my doctor about lung cancer screening?

Please do ask your doctor about lung cancer screening. It has been demonstrated to save lives in patients who are at high risk of developing lung cancer. If you are a current smoker or have smoked in the past it would be important to discuss this further with your doctor.

Should everyone be screened for lung cancer?

When determining whether someone should be screened for lung cancer, it is important to discuss the risks and the benefits. It has been shown that only people at a high risk of lung cancer will benefit from screening, whereas those who are not at high risk, unfortunately, may suffer harm. Currently, lung cancer screening is generally recommended for those between the ages of 55 and 80 who have smoked at least one packet of cigarettes a day for more than 30 years. This means that those people at the highest risk of lung cancer are those that should be screened. Unfortunately, it is currently not recommended to screen those people at lower risk since they may experience more harm than benefit. It is important to discuss this – the risks versus the benefits of lung cancer screening – with your doctor.

 

If you are concerned and would like to enquire about lung cancer screening, make an appointment with a specialist.

By Dr Neal Navani
Pulmonology & respiratory medicine

Dr Neal Navani is one of London's leading respiratory experts. He practises at a number of prominent medical establishments in the capital including University College London (UCL) Hospital, The Physician's Clinic and King Edward VII's Hospital. He specialises in endobronchial ultrasound (EBUS), bronchoscopy, coughs, asthma, lung cancer and smoking-related lung diseases. He also specialises in lung problems in people with cancer.

Graduating from Cambridge University with a MBBS in 1997, Dr Navani went on to complete his initial clinical medical training University College London, qualifying in 2000. He trained at Brompton and Hammersmith Hospitals in Reparatory Medicine before being awarded a Medical Research Council Fellowship in 2008. In 2011, he completed his PhD in University College London. Additionally, he obtained a MSc in Clinical Trials from the London School of Hygiene and Tropical Medicine. 

Dr Navani has over 20 years' experience in treating patients. His patients and their needs are at the centre of his approach. He is currently the lead clinician for the lung cancer and interventional bronchoscopy services at University College London Hospital. 

In addition to his clinical roles, Dr Navani is the co-lead of the National Lung Cancer Audit and an associate professor at University College London. He is an author of various peer-reviewed publications, the British Thoracic Society guideline, quality standards for bronchoscopy and forms an integral part of numerous other professional bodies. He is a member of a number of esteemed medical societies including the British Thoracic Society and the European Respiratory Society. He is also a fellow of the Royal College of Physicians.  

View Profile

Overall assessment of their patients


  • Related procedures
  • Depression
    Sleep disorders
    Snoring
    Rhinitis
    Obstructive sleep apnea
    Restless legs syndrome
    Autoimmune diseases
    Atypical pneumonia
    Asthma
    Methacholine challenge test
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.